FOR IMMEDIATE RELEASE - 9:00 AM AEST MELBOURNE 4 JUNE 2024 AND 19.00 PM EDT NEW YORK 3 JUNE MELBOURNE, Australia, June 04, 2024 (GLOBE NEWSWIRE) -- Brandon Capital, Australasia's leading life sciences venture capital firm, today announced the launch of its sixth fund, Brandon Capital Fund VI, with an initial close at A$270 million (US$180 million). This new fund will support the growth of Australian and New Zealand life sciences startups, invest in scale-ups, and expand Brandon Capital's international presence, particularly in the United Kingdom, Europe, and the United States. Fund VI is backed by existing Limited Partner (LP) investors, including Australian superannuation (pension) funds, and new investors. The fund remains open, with ongoing discussions with potential investors both locally and internationally. Brandon Capital's strategy focuses on early-stage innovations with strong scientific and commercial potential. The firm provides critical support, management, and investment to propel portfolio companies through their early growth stages. To date, Brandon Capital has raised over A$1 billion across five previous Funds and has completed more than 60 investments in new therapeutic, medical device, and healthtech companies, with numerous notable successful exits. The new ...